Hypertension Diagnostics, Inc. Newsroom


	Stanford University Invites Hypertension Diagnostics to Demonstrate CVProfilor^® System at Cardiovascular Nutrition Conference ST. PAUL, MN – April 10, 2002 – Hypertension Diagnostics, Inc. (NASDAQ SmallCap: HDII), announced today that it has been invited by Stanford University School of Medicine to exhibit at the 1st Bay Area Conference on “Controversies in Cardiovascular Nutrition” being held on Saturday, May 4, 2002 at the Stanford University School of Medicine. The conference is co-sponsored by Stanford University and the American College of Nutrition, and has been organized by renowned opinion leaders in the arena of cardiovascular nutrition. The conference is a one-day event and approximately 300 attendees are expected, including leaders in the fields of nutrition and cardiovascular medicine from top institutions across the country.
	Greg H. Guettler, President of Hypertension Diagnostics, said: “We are looking forward to introducing our CVProfilor^® DO-2020 System technology to physicians, other health care professionals and opinion leaders who specialize in cardiovascular nutrition by providing personal CVProfile™ tests to all attendees. Medical research suggests that factors such as diet, weight and level of physical activity may play a significant role in the development of cardiovascular disease. Similarly, the same interventions used to prevent cardiovascular disease are also effective in treating it. Nutrition appears to be one of many contributors to structural abnormalities of the arterial wall (that is, the endothelium) which precede atherosclerosis (that is hardening of the arteries) and cardiovascular events. The CVProfilor^® DO-2020 System offers a means to assess one’s vascular health (including endothelial function) by providing a painless, non-invasive measurement of both large and small artery elasticity.” Hypertension Diagnostics, Inc. designs, develops, manufactures and markets proprietary cardiovascular profiling systems for medical applications and clinical research. These systems are marketed to physicians, other health care professionals and researchers by a direct sales force and via distributors throughout the world. In addition to providing blood pressure values, the systems non-invasively detect subtle changes in the compliance or elasticity of both large and small arteries which is a unique feature of HDI’s technology. Forward-looking statements in this press release are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company wishes to caution readers not to place undue reliance on any forward-looking statements and to recognize that the statements are not a prediction of actual future results. Actual results could differ materially from those presented and anticipated in the forward-looking statements due to the risks and uncertainties set forth in the Company’s 2001 Annual Report on Form 10-KSB under the caption “Risk Factors,” as well as others not now anticipated. CVProfilor is a registered trademark of Hypertension Diagnostics, Inc. Hypertension Diagnostics, HDI/PulseWave, PulseWave and CVProfile are trademarks of Hypertension Diagnostics, Inc. All rights reserved. Investor Relations: Jens Dalsgaard and Tony Altavilla, Managing Directors Redwood Consultants, LLC Mill Valley, CA 94941 415-380-0500 Contact: Greg H. Guettler, President Return to the Main HDI Newsroom Back to Top

Copyright © 2007 Hypertension Diagnostics, Inc Last revised Sunday April 22, 2007 HDI Legal Information